Publications

5808 Results

A Phase II Study of MK-2206, an Allosteric Inhibitor of AKT as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction (GEJ) Cancer, a SWOG Cooperative Group Trial (S1005)

Authors
R Ramanathan;S McDonough;H Kennecke;S Iqbal;J Baranda;T Seery;H Lim;AF Hezel;G Vaccaro;CD Blanke
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 4041); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
Year
2014
Research Committee(s)
Gastrointestinal
Study Number(s)
S1005

US Intergroup Phase II Trial (SWOG S1108) of Alisertib, an Investigational Aurora A Kinase (AAK) Inhibitor, in Patients with Peripheral T-Cell Lymphoma (PTCL) (NCT01466881)

Authors
P Barr;H Li;C Spier;D Mahadevan;J Friedberg;M Leblanc;M Ul Haq;C Flowers;N Wagner-Johnston;SM Horwitz;B Cheson;TP Miller;RI Fisher
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 8523); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session;
Year
2014
Research Committee(s)
Lymphoma
Study Number(s)
S1108

A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of AromataseInhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer: SWOG S1202

Authors
NL Henry;J Unger;A Schott;L Hansen;D Lew;J Wade;C Moinpour;GN Hortobagyi;FL Meyskens
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr TPS9662); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
Year
2014
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S1202

SWOG 1211: a randomized phase I/II study of optimal induction therapy of bortezomib, dexamethasone and lenalidomide with or without elotuzumab for newly diagnosed high risk multiple myeloma (HRMM)

Authors
SZ Usmani;A Hoering;R Sexton;S Ailwahdi;JJ Shah;S Fredette;B Durie;J Zonder;M Dhodapkar;SV Rajkumar;T Zimmerman;P Richardson;RZ Orlowski
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr TPS8624); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
Year
2014
Research Committee(s)
Myeloma
Study Number(s)
S1211

SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy (ADT) + TAK-700 with ADT + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (HSPC) (NCT01809691)

Authors
N Agarwal;C Tangen;M Hussain;P Lara;C Higano;D Vaena;G MacVicar;H Li;T Cirspino;DI Quinn;N Vogelzang;IM Thompson
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr TPS5102);ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
Year
2014
Research Committee(s)
Genitourinary
Study Number(s)
S1216

Meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 4,798 patients

Authors
P Blanchard;AMW Lee;J Leclercq;S Marquet;WT Ng;J Ma;ATC Chan;P Huang;G Zhu;DTT Chua;HQ Mai;J Wee;DLW Kwong;J Moon;KH Chi;G Fountzilas;M Hareyama;L Zhang;J Bourhis;J-P Pignon
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 6022); ASCO (May 30-June 3, 2014, Chicago, IL), poster highlights session;
Year
2014
Research Committee(s)
Head and Neck
Study Number(s)
SWOG-8892 (INT-0099) (EST-2388) (RTOG-8817)

Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa)

Authors
LA Carey;WT Barry;B Pitcher;K Hoadley;MCU Cheang;IE Krop;NL Henry;DA Berry;CM Perou;EP Winer;CA Hudis
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 506); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), oral session;
Year
2014
Research Committee(s)
Breast

CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (uMCRC).

Authors
AP Venook;D Niedzwiecki;H-J Lenz;F Innocenti;MR Mahoney;BH O'Neil;JE Shaw;BN Polite;H Hochster;JN Atkins;RM Goldberg;RJ Mayer;RL Schilsky;M Bertagnolli;CD Blanke
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr LBA3); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), scientific plenary session (oral);
Year
2014
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

NCI pilot intervention program to assist accrual for challenging late phase clinical trials

Authors
A Denicoff;H Massett;E Souhan;JJ Welch;N Seibel;RF Little;BS Mann;K DiPiazza;M Rossmann;S Hartson Stine;R Lambersky;F Desanto;F Fonzi;D Schrag;RA Abrams;DJ Adelstein;PD Brown;M Mooney;J Abrams
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 6617); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
Year
2014
Research Committee(s)
Leukemia
Study Number(s)
S1117

Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial

Authors
C Sweeney;H-Y Chen;MA Carducci;G Liu;D Jarrad;M Eisenberger;Y-N Wong;NM Hahn;M Kohli;N Vogelzang;MM Cooney;R Dreicer;J Picus;DH Shevrin;M Hussain;JA Garcia;RS DiPaola
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr LBA2); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), scientific plenary session (oral);
Year
2014
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/E3805